entertainment -WSS

entertainment

author：focus 2025-10-01 05:39:52 - browse：79

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： What the cancer research community can learn from the Covid response

hotspot

explore

WSS

White House drug shortage group privately met with industry

What Henrietta Lacks settlement says about racism in medicine

ProMED, early warning system on disease outbreaks, in peril

ProMED, early warning system on disease outbreaks, in peril

Dramatically reducing cancer deaths requires the PASTEUR Act

'Ancient DNA,' 23andMe reveal African American ancestries

hotspot

entertainment

knowledge

Activists slam private health insurers over coverage restrictions

Victims of gun violence feel impacts long after bullet wound

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Diversify hospital leadership teams to protect BIPOC patient health

Psychedelics group wrestles with new pharma identity

A cyberattack has disrupted hospitals and health care in several states

Anesthesiologist group: stop taking Ozempic before surgery

2 US Navy sailors arrested for allegedly spying for China

In age of alternative facts, a scholarly course on calling out crap

FDA approves potent Eli Lilly obesity drug, Zepbound

hotspot

ProMED, early warning system on disease outbreaks, in peril

Extreme heat events are a public health emergency

FDA approves potent Eli Lilly obesity drug, Zepbound

Humana, CVS hope to turn members into patients at clinics

Will General Catalyst be the first of many hospital takeovers?

STAT Executive Editor Rick Berke on STAT's 8th birthday

hotspot

hotspot

explore

leisure time